CGAU vs. BIB
CGAU (Centerra Gold Inc) is a stock, while BIB (ProShares Ultra Nasdaq Biotechnology) is Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%). Over the past 5 years, CGAU returned 16.69%/yr vs -0.49%/yr for BIB. At a 0.23 correlation, their price movements are largely independent.
Performance
CGAU vs. BIB - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CGAU achieves a 8.63% return, which is significantly lower than BIB's 15.71% return.
CGAU
- 1D
- -3.12%
- 1M
- -5.77%
- YTD
- 8.63%
- 6M
- 4.70%
- 1Y
- 123.87%
- 3Y*
- 42.55%
- 5Y*
- 16.69%
- 10Y*
- —
BIB
- 1D
- 2.86%
- 1M
- 12.61%
- YTD
- 15.71%
- 6M
- 10.09%
- 1Y
- 99.30%
- 3Y*
- 20.78%
- 5Y*
- -0.49%
- 10Y*
- 10.02%
CGAU vs. BIB - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CGAU Centerra Gold Inc | 8.63% | 159.49% | -1.45% | 19.37% | -32.55% | -14.48% |
BIB ProShares Ultra Nasdaq Biotechnology | 15.71% | 59.21% | -9.84% | -1.06% | -28.85% | -3.82% |
Correlation
The correlation between CGAU and BIB is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Apr 15, 2021 | 0.23 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CGAU vs. BIB — Risk / Return Rank
CGAU
BIB
CGAU vs. BIB - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Centerra Gold Inc (CGAU) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CGAU | BIB | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.09 | ||
| Sortino ratioReturn per unit of downside risk | -0.47 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.36 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 4.22 | 5.90 | -1.68 |
| Martin ratioReturn relative to average drawdown | 11.85 | 18.03 | -6.17 |
Loading charts...
Drawdowns
CGAU vs. BIB - Drawdown Comparison
The maximum CGAU drawdown since its inception was -63.47%, smaller than the maximum BIB drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for CGAU and BIB.
Loading charts...
Drawdown Indicators
| CGAU | BIB | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.47% | -67.24% | +3.77% |
Max Drawdown (1Y)Largest decline over 1 year | -29.50% | -16.92% | -12.58% |
Max Drawdown (3Y)Largest decline over 3 years | -30.24% | -45.30% | +15.06% |
Max Drawdown (5Y)Largest decline over 5 years | -63.47% | -65.86% | +2.39% |
Max Drawdown (10Y)Largest decline over 10 years | — | -66.20% | — |
Current DrawdownCurrent decline from peak | -25.77% | -14.92% | -10.85% |
Average DrawdownAverage peak-to-trough decline | -29.55% | -32.70% | +3.15% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.49% | 5.53% | +4.96% |
Volatility
CGAU vs. BIB - Volatility Comparison
Centerra Gold Inc (CGAU) has a higher volatility of 19.02% compared to ProShares Ultra Nasdaq Biotechnology (BIB) at 13.74%. This indicates that CGAU's price experiences larger fluctuations and is considered to be riskier than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CGAU | BIB | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.02% | 13.74% | +5.28% |
Volatility (6M)Calculated over the trailing 6-month period | 42.99% | 31.45% | +11.54% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.29% | 40.49% | +11.80% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 47.12% | 43.61% | +3.51% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.86% | 46.39% | +2.47% |
Dividends
CGAU vs. BIB - Dividend Comparison
CGAU's dividend yield for the trailing twelve months is around 1.31%, more than BIB's 0.53% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.53% | 0.77% | 1.69% | 0.07% | 0.03% |
CGAU Centerra Gold Inc | 1.31% | 1.39% | 3.59% | 3.45% | 0.00% |
Frequently Asked Questions
CGAU and BIB have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CGAU has higher volatility (19.02%) compared to BIB (13.74%). In terms of maximum drawdown, CGAU dropped -63.47% vs BIB's -67.24%.
BIB currently has the higher Sharpe Ratio (2.47 vs 2.39), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CGAU and BIB
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer